Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19699-24] to C5a
- Suitable for: WB, IP
- Reacts with: Human
Product nameAnti-C5a antibody [EPR19699-24]
See all C5a primary antibodies
DescriptionRabbit monoclonal [EPR19699-24] to C5a
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Human
Recombinant fragment within Human C5a aa 200-1100. The exact sequence is proprietary.
Database link: P01031
- WB: Human serum. IP: Human serum.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab202039 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
RelevanceActivation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
Anti-C5a antibody [EPR19699-24] (ab202039) at 1/1000 dilution + Human serum at 20 µg
VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Exposure time: 3 minutes
C5 is cleaved into C5α and C5β and this antibody recognizes the C5α. The molecular weight observed is consistent with what has been described in the literature (PMID: 23401592)
C5a was immunoprecipitated from 0.35 mg human serum 10μg with ab202039 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab202039 at 1/2000 dilution (0.26 μg/ml). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/10,000 dilution.
Lane 1: Human serum 10μg.
Lane 2: ab202039 IP in human serum.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab202039 in human serum.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
This antibody recognizes C5a.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab202039 has not yet been referenced specifically in any publications.